BridgeBio Pharma, Inc. — Director's Dealing 2022

Jan 4, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BridgeBio Pharma, Inc. (BBIO)
CIK: 0001743881
Period of Report: 2021-12-29

Reporting Person: Hassan Fred (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-12-29	Common Stock	P	19300	$14.1653	Acquired	19300	Direct

Footnotes

F1: Represents the weighted average purchase price of the shares purchased from $14.1250 to $14.2300 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions as reported in this footnote.